{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736+%2B+Tremelimumab&page=3", "query": { "intervention": "MEDI4736 + Tremelimumab", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736+%2B+Tremelimumab&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MEDI4736+%2B+Tremelimumab&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T11:03:05.657Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Carcinoma NSCLC" ], "interventions": [ { "name": "Durvalumab +Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + cisplatin", "type": "DRUG" }, { "name": "Pemetrexed + carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 953, "start_date": "2015-11-03", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 15, "location_summary": "Anaheim, California • San Diego, California • Santa Rosa, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542293" }, { "nct_id": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Anti-PD-L1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Anti-PD1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Monitoring", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surveillance", "type": "BEHAVIORAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 535, "start_date": "2026-04-08", "completion_date": "2028-10-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Corona, California • Duarte, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288034" }, { "nct_id": "NCT04989218", "title": "Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cholangiocarcinoma" ], "interventions": [ { "name": "Novel combination of chemotherapy and immunotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 1, "start_date": "2023-01-30", "completion_date": "2024-05-01", "has_results": true, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04989218" }, { "nct_id": "NCT03164616", "title": "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Abraxane + carboplatin", "type": "DRUG" }, { "name": "Gemcitabine + cisplatin", "type": "DRUG" }, { "name": "Gemcitabine + carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + carboplatin", "type": "DRUG" }, { "name": "Pemetrexed + cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1186, "start_date": "2017-06-01", "completion_date": "2027-11-15", "has_results": true, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03164616" }, { "nct_id": "NCT03937830", "title": "Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Cancer", "Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma" ], "interventions": [ { "name": "durvalumab", "type": "DRUG" }, { "name": "Doxorubicin-Eluting Beads", "type": "DRUG" }, { "name": "TACE", "type": "PROCEDURE" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 27, "start_date": "2021-03-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03937830" }, { "nct_id": "NCT03837899", "title": "Durvalumab and Tremelimumab for Pediatric Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Cancer", "Solid Tumor Pediatric", "Hematological Malignancies" ], "interventions": [ { "name": "Durvalumab / Tremelimumab Combination Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 50, "start_date": "2019-03-07", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837899" }, { "nct_id": "NCT02117219", "title": "Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "MEDI4736 Evaluate MEDI4736 in MDS", "type": "BIOLOGICAL" }, { "name": "VIDAZA", "type": "DRUG" }, { "name": "tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 67, "start_date": "2014-05-20", "completion_date": "2019-04-30", "has_results": false, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02117219" }, { "nct_id": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 103, "start_date": "2024-04-04", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 47, "location_summary": "Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008093" }, { "nct_id": "NCT03911557", "title": "Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumor, Solid" ], "interventions": [ { "name": "Durvalumab and Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John L. Villano, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-06-08", "completion_date": "2025-10-10", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911557" }, { "nct_id": "NCT03277482", "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Gynecological Cancer", "Metastatic Cervical Cancer", "Metastatic Ovarian Cancer", "Metastatic Vaginal Cancer", "Metastatic Vulvar Cancer", "Metastatic Endometrial Cancer", "Recurrent Cervical Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Recurrent Endometrial Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2018-06-01", "completion_date": "2022-07-15", "has_results": false, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-10T11:03:05.657Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277482" } ] }